Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02261363 · ClinicalTrials.gov registry record · NA
The Moment Study: Mixed Method E-cigarette Study
A NA study of Smoking, sponsored by Truth Initiative.
- Completed
- Registry status
- NA
- Development phase
- 117
- Enrollment target
- 1
- Study location
NCT02261363: Completed NA study of Smoking, sponsored by Truth Initiative.
NCT02261363 is a NA study of Smoking that has completed, run by Truth Initiative. The registered enrollment target is 117 participants, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02261363, a NA study of Smoking, has completed, sponsored by Truth Initiative.
- COMPLETED
- Registry status
- NA
- Development phase
- 117 participants
- Enrollment target
- 1
- Study location
Study Summary
The universe of tobacco products is expanding, with new noncombustible products gaining popularity even as the reduction in prevalence of cigarette smoking slows or stalls. E-cigarettes, or Electronic Nicotine Delivery Systems (ENDS), are the most prevalent of these emerging noncombustible products. With sales increasing rapidly and more efficient pulmonary delivery devices under development, ENDS are likely to play an increasing role in the future tobacco market. Little is known about the cognitions and behaviors leading to or sustaining ENDS use. Smokers may use ENDS to subvert smoking restrictions, to reduce perceived smoking harms, or for smoking cessation. Evidence about ENDS use is emerging from national surveillance and laboratory research, but the majority of information on ENDS is limited to retrospective surveys and convenience samples of White male ENDS users. The investigators research suggests Black smokers are less likely than White smokers to try and be current ENDS users, perhaps due to a greater degree of perceived harm associated with ENDS, a preference for menthol, or cultural norms. Thus, it is timely and critical to study how all smokers, including Blacks and menthol smokers, experience and initiate ENDS use employing valid, innovative research methods.
Primary Outcome
Change in the average number of cigarettes per day comparing average cigarettes per day on study day 6 (last day of cigarette-only use) to average cigarettes per day on study day 7 (first day of e-cigarette and cigarette use).
Conditions Studied
Interventions
- OTHER Ecig group 1
Study Locations (1)
District of Columbia
- American Legacy Foundation - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-08 |
| Phase | NA |
What the finished NCT02261363 record still lists
NCT02261363 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 1 intervention - of which Ecig group 1 is the first listed.
NCT02261363 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02261363 about?
NCT02261363 is a clinical study titled "The Moment Study: Mixed Method E-cigarette Study". The universe of tobacco products is expanding, with new noncombustible products gaining popularity even as the reduction in prevalence of cigarette smoking slows or stalls. E-cigarettes, or Electronic Nicotine Delivery Systems (ENDS), are the most prevalent of these emerging noncombustible products....
What is the current status of trial NCT02261363?
This trial is currently completed. It is a NA study. The enrollment target is 117 participants. The study started on 2014-08. Estimated completion is 2016-08.
What conditions does trial NCT02261363 study?
This clinical trial studies the following conditions: Smoking.
What interventions are being tested in trial NCT02261363?
The interventions under investigation include: Ecig group 1 (OTHER).
Who is sponsoring clinical trial NCT02261363?
This trial is sponsored by Truth Initiative, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02261363 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02261363's enrollment target sits among peer trials
117 66th of 123 higher than 57 of 123 other Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Alternatives for Reducing Harm Using E-cigarettes
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Enhancing Motivation to Quit Smoking Via Self-Help Intervention Targeted to Cancer Type
RECRUITING · NA
-
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
RECRUITING · NA
-
Take A Break - Rural
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia